Kathiawad Today

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size, Share, Trends, Leading Companies, Emerging Drugs, and Epidemiology Forecast

 Breaking News
  • No posts were found

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size, Share, Trends, Leading Companies, Emerging Drugs, and Epidemiology Forecast

February 20
19:45 2021
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size, Share, Trends, Leading Companies, Emerging Drugs, and Epidemiology Forecast

Delveinsight Business Research LLP

DelveInsight’s “Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Insights, Epidemiology, and Market Forecast 2030” report delivers an in-depth understanding of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), historical and forecasted epidemiology as well as the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Chronic inflammatory demyelinating polyneuropathy (CIDP) is a rare neurological disorder characterized by progressive weakness and impaired sensory function in the legs and arms mainly caused by damage to the myelin sheath (the fatty covering that wraps around and protects nerve fibers) of the peripheral nerves. The disease often presents with symptoms that include tingling or numbness (beginning in the toes and fingers), weakness of the arms and legs, loss of deep tendon reflexes (areflexia), fatigue, and abnormal sensations.

Get FREE sample copy at: 
https://www.delveinsight.com/sample-request/chronic-inflammatory-demyelinating-polyneuropathy-cidp-market

The Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market report also covers emerging drugs, current treatment practices, CIDP market share of the individual therapies, current and forecasted CIDP Market Size from 2017 to 2030 segmented by seven major markets. 

The report provides a detailed current CIDP treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market. 

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Key Facts

  • According to DelveInsight estimates, the total prevalent population of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in 7MM was found to be 44,843 in 2017.

  • Among the EU5 countries, France has the highest prevalent population of CIDP with 3,697 cases, followed by the UK.

  • Among the European 5 countries, Spain had the lowest cases of CIDP, i.e., estimated to be 1,727 in 2017.

Key Benefits of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Report

  • Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market report provides an in-depth analysis of CIDP Market Size, Share, Trend, Epidemiology and Market Forecast till 2030, in 7 major markets i.e. EU5 (Germany, Italy, Spain, France, and the UK), Japan, and the United States.

  • The CIDP market report will help in developing business strategies by understanding the CIDP Market trends & developments, key players, and future market competition that will shape and drive the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market in the upcoming years.

  • The Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market report covers current treatment practices, emerging drugs, market share of the individual therapies in 7 MM.

  • The report provides a detailed assessment of the CIDP market in terms of market drivers & barriers, Unmet Needs, market opportunities, patient population,  comparative analysis of pipeline products with detailed clinical profiles, and other factors. 

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market

As per the Delveinsight, the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market size in the 7MM was found to be 1194.55 Million in 2017.

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market size is expected to increase during the forecast period owing to the rise in prevalence of CIDP and the growing adoption of diagnostic criteria along with adherence to the treatment guidelines for optimal therapy.

The CIDP market outlook section of the report helps to build a detailed comprehension of the historic, current, and forecasted CIDP market trends by analyzing the impact of current therapies on the market, unmet needs, drivers, and barriers, and demand for better technology. 

The report gives a thorough detail of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, and view of the key opinion leaders. 

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Epidemiology

Assessments as per DelveInsight’s analysts among the overall prevalence of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), typical CIDP reportedly higher as compared to atypical CIDP and is subjected to increase rapidly in the coming years. In 2017, prevalent cases of typical and atypical CIDP in the US varied as 10,342 and 9,936, respectively.

The CIDP epidemiology section covers insights about the historical and current Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) patient pool and forecasted trends for every seven major countries (i.e. the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.

It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.  

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Drugs Uptake and Key Market Players

The Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Drugs Uptake section focuses on the rate of uptake of the potential drugs recently launched in the CIDP market or expected to get launched in the market during the study period. The analysis covers Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market uptake by drugs; patient uptake by therapies; and sales of each drug.    

Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Companies:
Teijin Pharma
Octapharm
Shire
Takeda
Argenx
UCB Biopharma
MedDay Pharmaceuticals
GeNeuro Pharmaceuticals
Momenta Pharmaceuticals
And many others.

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Therapies Covered in the Report Include:
GGS-CIDP
NewGam
HyQvia
Efgartigimod
Rozanolixizumab
MD-1003
GNbAC1
M254
And many more.

Table of Content

1. Key Insights

2. Executive Summary 

3. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Competitive Intelligence Analysis

4. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Overview at a Glance

5. CIDP Disease Background and Overview

6. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Patient Journey

7. CIDP Epidemiology and Patient Population

8. CIDP Treatment Algorithm, Current Treatment, and Medical Practices

9. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Unmet Needs

10. Key Endpoints of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Treatment

11. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Marketed Products

12. CIDP Emerging Therapies

13. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Seven Major Market Analysis

14. Attribute Analysis

15. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Outlook (7 major markets)

16. CIDP Access and Reimbursement Overview

17. KOL Views on the CIDP Market.

18. CIDP Market Drivers

19. CIDP Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

Related Reports
Chronic Inflammatory Demyelinating Polyneuropathy Epidemiology Forecast
DelveInsight’s Chronic inflammatory demyelinating polyneuropathy (CIDP) Epidemiology Forecast 2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of CIDP in the United States, EU5, and Japan.

Chronic inflammatory demyelinating polyneuropathy Pipeline Insight
Chronic inflammatory demyelinating polyneuropathy (CIDP) Pipeline Insight, 2020 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the CIDP market.

 About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd. 2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/